Evaluation of the children with C3 glomerulopathy

Area of Science:

• Nephrology
• Immunology
• Pediatrics

Background:

• C3 glomerulopathy (C3G) is a rare kidney disease with varied clinical presentations.
• It involves complement system dysregulation, leading to glomerular damage.
• Understanding C3G in children is crucial for effective management.

Purpose of the Study:

• To document clinical and laboratory findings in pediatric C3G.
• To evaluate the response to various treatments, including immunosuppressants and eculizumab.
• To assess the prognosis of children diagnosed with C3G.

Main Methods:

• Retrospective review of medical records of patients diagnosed with membranoproliferative glomerulonephritis (MPGN).
• Re-examination of kidney biopsy materials for C3G diagnosis based on dominant C3 staining.
• Inclusion criteria focused on immunofluorescence and light microscopy findings.

Main Results:

• Twelve pediatric MPGN patients met C3G criteria; most showed dominant C3 staining.
• One patient achieved remission with ACE inhibitors alone.
• Others received immunosuppressive therapy; two required eculizumab, with one progressing to end-stage renal failure.

Conclusions:

• C3G exhibits heterogeneous clinical features and outcomes in children.
• Treatment strategies for C3G must be individualized.
• Eculizumab represents a potential therapeutic option for refractory C3G, particularly in early stages, but its efficacy is variable.